These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32089398)

  • 41. Bone marrow-derived conventional, but not cloned, mesenchymal stem cells suppress lymphocyte proliferation and prevent graft-versus-host disease in rats.
    Kitazawa Y; Li XK; Xie L; Zhu P; Kimura H; Takahara S
    Cell Transplant; 2012; 21(2-3):581-90. PubMed ID: 22793067
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ex Vivo Generated Human Cord Blood Myeloid-Derived Suppressor Cells Attenuate Murine Chronic Graft-versus-Host Diseases.
    Lim JY; Ryu DB; Park MY; Lee SE; Park G; Kim TG; Min CK
    Biol Blood Marrow Transplant; 2018 Dec; 24(12):2381-2396. PubMed ID: 30006304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Circulating CD14(+) HLA-DR(-/low) myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease.
    Yin J; Wang C; Huang M; Mao X; Zhou J; Zhang Y
    Cancer Med; 2016 Jul; 5(7):1654-69. PubMed ID: 27109254
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-pharmacologic strategies in hematopoietic stem cell transplantation.
    Schneiderman J
    Curr Pharm Des; 2008; 14(20):1987-96. PubMed ID: 18691109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.
    Zhang L; Yu J; Wei W
    Front Immunol; 2018; 9():1087. PubMed ID: 29868032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Umbilical cord-derived mesenchymal stem cells promote myeloid-derived suppressor cell enrichment by secreting CXCL1 to prevent graft-versus-host disease after hematopoietic stem cell transplantation.
    Wang R; Wang X; Yang S; Xiao Y; Jia Y; Zhong J; Gao Q; Zhang X
    Cytotherapy; 2021 Nov; 23(11):996-1006. PubMed ID: 34465514
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
    Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
    J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased Foxp3
    Chen YB; Efebera YA; Johnston L; Ball ED; Avigan D; Lekakis LJ; Bachier CR; Martin P; Duramad O; Ishii Y; Han S; Jung YJ; Lee D; Kunkel L; Negrin RS; Bui JD
    Biol Blood Marrow Transplant; 2017 Apr; 23(4):625-634. PubMed ID: 28104514
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mesenchymal stem cells attenuate rat graft-versus-host disease.
    Fujino M; Zhu P; Kitazawa Y; Chen JM; Zhuang J; Li XK
    Methods Mol Biol; 2014; 1213():341-53. PubMed ID: 25173396
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.
    Wolf D; Bader CS; Barreras H; Copsel S; Pfeiffer BJ; Lightbourn CO; Altman NH; Komanduri KV; Levy RB
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Graft-vs-leukemia activity and graft-vs-host disease induced by allogeneic Th1- and Th2-type CD4+ T cells in mice.
    Zeis M; Uharek L; Hartung G; Glass B; Steinmann J; Schmitz N
    Hematol J; 2001; 2(2):136-44. PubMed ID: 11424006
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
    Zhang J; Chen HM; Ma G; Zhou Z; Raulet D; Rivera AL; Chen SH; Pan PY
    Leukemia; 2019 Aug; 33(8):2078-2089. PubMed ID: 30737483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.
    D'Aveni M; Notarantonio AB; Bertrand A; Boulangé L; Pochon C; Rubio MT
    Front Immunol; 2020; 11():989. PubMed ID: 32528476
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute graft-versus-host disease: new treatment strategies.
    Paczesny S; Choi SW; Ferrara JL
    Curr Opin Hematol; 2009 Nov; 16(6):427-36. PubMed ID: 19812490
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies.
    Zeiser R; Marks R; Bertz H; Finke J
    Ann Hematol; 2004 Sep; 83(9):551-65. PubMed ID: 15449032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced efficacy of mesenchymal stromal cells in preventing graft-versus-host disease in an in vivo model of haploidentical bone marrow transplant with leukemia.
    Oviedo A; Yañez R; Colmenero I; Aldea M; Rubio A; Bueren JA; Lamana ML
    Cell Transplant; 2013; 22(8):1381-94. PubMed ID: 23044223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of mesenchymal stem cells in hematopoietic stem cell transplantation: prevention and treatment of graft-versus-host disease.
    Zhao L; Chen S; Yang P; Cao H; Li L
    Stem Cell Res Ther; 2019 Jun; 10(1):182. PubMed ID: 31227011
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.